HPP has launched a report on genetic testing for BRCA mutations, developed in collaboration with a group of expert contributors from across Europe.
Genetic mutations in the BRCA1 and BRCA2 genes are associated with a significantly increased risk of breast cancer. Yet many people at high risk of developing BRCA-related breast cancer cannot access a genetic test, and therefore miss out on support to decide how to act to reduce their risk of developing cancer. For those who are able to access genetic testing, it is not always provided in the most appropriate or effective way.
The European-level report identifies four priority areas where policy change is needed to improve access to genetic testing and associated services for people at high risk of BRCA-related breast cancer. There are also seven country profiles, which take a closer look at the state of play in France, Germany, Ireland, Italy, Israel, Sweden and the United Kingdom.